Aeglea Bio Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Good afternoon, everyone. My name is Tessa Romero. And I'm one of the biotechnology analysts here at JPMorgan.
On behalf of myself, Anupam Rama, Matt Bannon, I am pleased to welcome to the stage Aeglea. And presenting on behalf of the company is CEO Anthony Quinn.
Tony?
Yes. Thank you for the kind introduction. It's great to be here. Looking forward to presenting at JPMorgan today.
I will be making some forward-looking statements with risks and uncertainties. Obviously, please refer to our SEC documents.
So at Aeglea, we are thinking about the science of human enzymes very differently. We're actually reimagining the potential of these natural human catalysts to address unmet medical need for patients with a range of rare genetic disorders. We have a platform that allows us to develop innovative therapeutics with unique mechanisms that can actually have the potential to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
